bluuebunny/crossref_metadata_2025_split huggingface dataset:
Synthesis, Characterization and in vitro Biological Studies of Novel Cyano Derivatives of N‐Alkyl and N‐Aryl Piperazine.
Authors: Chaudhary Preeti , Nimesh Surendra , Yadav Veena , Verma Akhilesh Kr. , Kumar Rupesh 
Published: August 2007

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Cyclization of Aroylacetic Acids 2‐Carboxyphenylamides (III) into 2‐[(Z)‐2‐Aryl‐2‐hydroxy‐1‐ethenyl]‐4H‐3,1‐benzoxazin‐4‐ones (IV). Crystal and Molecular Structure of 2‐[(Z)‐2‐Hydroxy‐2‐phenyl‐1‐ethenyl]‐4H‐3,1‐benzoxazin‐4‐one.
Authors: Vostrov E. S. , Novikov A. A. , Maslivets A. N. , Aliev Z. G. 
Published: August 2007

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Synthesis of New 2,3‐Dihydro‐1H‐pyrido[3,2,1‐kl]phenoxazines.
Authors: Zhandarev V. V. , Goshin M. E. , Kazin V. N. , Smirnov A. V. , Filimonov S. I. , Plakhtinskii V. V. 
Published: August 2007

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Synthesis and Antimicrobial Activities of Some Novel 1,2,4‐Triazolo[3,4‐b]‐1,3,4‐thiadiazoles and 1,2,4‐Triazolo[3,4‐b]‐1,3,4‐thiadiazines Carrying Thioalkyl and Sulfonyl Phenoxy Moieties.
Authors: Karabasanagouda T. , Adhikari Airody Vasudeva , Shetty N. Suchetha 
Published: August 2007

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Fatty Acid Hydrazides in Heterocyclic Synthesis: Synthesis of 1,2‐Diazepine and Pyridazine Derivatives.
Authors: Zaki Magdi E. A. , Yousef Elham A. A. , Hassanien Abu Zeid A. 
Published: August 2007

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Two New Iridoid Glycosides from Lagotis yunnanensis
Authors: Yang Xiao‐Dong , Yang Li‐Juan , Yang Shu , Zhao Jing‐Feng , Zhang Hong‐Bin , Li Liang 
Published: August 2007

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Efficient Synthesis of Brussalexin A (I), a Remarkable Phytoalexin from Brussels Sprouts.
Authors: Pedras M. Soledade C. , Zheng Qing‐An , Sarwar Mohammed G. 
Published: August 2007

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
MED‐SuMoLig: A New Ligand‐Based Screening Tool for Efficient Scaffold Hopping.
Authors: Sperandio Olivier , Andrieu Olivier , Miteva Maria A. , Vo Minh‐Quang , Souaille Marc , Delfaud Francois , Villoutreix Bruno O. 
Published: August 2007

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Evaluation of Pseudomonas aeruginosa Deacetylase LpxC Inhibitory Activity of Dual PDE4—TNFα Inhibitors: A Multiscreening Approach.
Authors: Kadam Rameshwar U. , Garg Divita , Chavan Archana , Roy Nilanjan 
Published: August 2007

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Synthesis, SAR and Antibacterial Studies of Novel Chalcone Oxazolidinone Hybrids.
Authors: Selvakumar N. , Kumar G. Sunil , Azhagan A. Malar , Rajulu G. Govinda , Sharma Shikha , Kumar M. Sitaram , Das Jagattaran , Iqbal Javed , Trehan Sanjay 
Published: August 2007

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Estrogen Receptor Ligands. Part 16. 2‐Aryl Indoles as Highly Subtype Selective Ligands for ERα.
Authors: Dykstra Kevin D. , et al. et al. 
Published: August 2007

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Light Energy Conversion and Storage with Soft Carbonaceous Materials that Solidify Mesoscopic Electrochemical Interfaces
Authors: Miyasaka Tsutomu , Ikeda Nobuyuki , Murakami Takurou N. , Teshima Kenjiro 
Published: August 2007

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Mechanisms Underlying Enhanced Vasodilator Responses to Various Vasodilator Agents Following Endothelium Removal in Rat Mesenteric Resistance Arteries
Authors: Iwatani Yukiko , Numa Hiromi , Atagi Saori , Takayama Fusako , Mio Mitsunobu , Kawasaki Hiromu 
Published: August 2007

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
First‐Principles Modelling of Earth and Planetary Materials at High Pressures and Temperatures
Authors: Gillan M. J. , Alfe D. , Brodholt J. , Vocadlo L. , Price G. D. 
Published: August 2007

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Sensory and Chemical Analysis Methods for Earthy and Musty Odors in Drinking Water Caused by Geosmin and 2‐Methylisoborneol
Authors: Wang Z. , Suffet I. H. , Al‐Samarrai H. 
Published: August 2007

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Plasma Catecholamines and Ischemic Heart Disease
Authors: Slavíková Jana , Kuncová Jitka , Topolčan Ondřej 
Published: August 2007

AbstractPlasma levels of norepinephrine and epinephrine were measured in 84 patients aged 56 ± 9 (mean ± SD) years with chronic ischemic heart disease (IHD), anterior acute myocardial infarction (AMI), posterior AMI, acute or chronic IHD associated with various types of electrical instability and in the control subjects. During the first day of hospitalization, plasma epinephrine levels were higher in patients with AMI in both localizations and chronic IHD in comparison with control values. There were no significant differences in plasma epinephrine levels among these groups of patients. However, in the same time period, plasma norepinephrine concentrations in patients with chronic IHD and posterior AMI did not differ from the control values; in patients with anterior AMI they reached by ∼60% higher values than in the control group. Moreover, all myocardial lesions showing different types of electrical instability were associated with increased plasma levels of both norepinephrine and epinephrine. In conclusion, high plasma levels of epinephrine may result from sympathoadrenal activation. High plasma levels of norepinephrine in patients with anterior AMI and no change in patients with posterior AMI suggest a rather myocardial than an extramyocardial origin of plasma norepinephrine level in anterior AMI. Norepinephrine released from the ischemic area might contribute to the electrical instability of the myocardium and generation of dysrrhythmias. Copyright © 2007 Wiley Periodicals, Inc.
A placebo‐controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome
Authors: Jatoi Aminah , Dakhil Shaker R. , Nguyen Phuong L. , Sloan Jeff A. , Kugler John W. , Rowland Kendrith M. , Soori Gamini S. , Wender Donald B. , Fitch Tom R. , Novotny Paul J. , Loprinzi Charles L. 
Published: August 2007

AbstractBACKGROUND.Tumor necrosis factor‐α (TNF‐α) is a putative mediator of the cancer anorexia/weight loss syndrome. The current study was designed to determine whether etanercept (a dimeric fusion protein consisting of the extracellular ligand‐binding portion of the human 75‐kilodalton TNF receptor linked to the Fc portion of human immunoglobulin [Ig] G1) could palliate this syndrome.METHODS.A total of 63 evaluable patients were randomly assigned to receive either etanercept at a dose of 25 mg subcutaneously twice weekly versus a comparably administered placebo. All patients had an incurable malignancy, acknowledged loss of weight and/or appetite as a concern, and reported a weight loss of >2.27 kg over 2 months and/or a daily intake of <20 calories/kg body weight.RESULTS.Over time, weight gain was found to be minimal in both treatment arms; no patient gained ≥10% of their baseline weight. Previously validated appetite questionnaires revealed negligible improvements in both treatment arms. The median survival was also comparable (175 days vs 148 days in etanercept‐treated and placebo‐exposed patients, respectively; P = .82). Finally, preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%). Infection rates were negligible in both groups. Genotyping for TNF‐α‐238 and TNF‐α‐308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the −238 G/A genotype and relatively less favorable survival.CONCLUSIONS.Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease. Cancer 2007. © 2007 American Cancer Society.
The Hydra Parallel Programming System
Authors: Powers Franklin E. , Alaghband Gita 
Published: August 2007

AbstractThe Hydra Parallel Programming System, a new parallel language extension to Java, and its supporting software are described. It is a fairly simple yet powerful language designed to address a number of areas that have not received much attention. One of these areas is the recompilation of parallel programs at runtime to allow a parallel program to adapt to the architecture it is executing on. The first version of this software system focuses on smaller Symmetric Multiprocessing and compatible architectures which are becoming more common. This particular class of machines has a great need for more options in the area of parallel programming among the vastly popular Java language programmers. Hydra programs will run as sequential Java on machines that do not have the parallel support or do not have an implemented Hydra runtime system without requirement of any modifications to the program. This paper describes the language, compares it with other languages (specifically with JOMP, an OpenMP implementation for Java), presents a brief discussion on compiling and executing Hydra programs, presents some sample benchmarks and their performance on three platforms, and concludes with a discussion of issues and future directions for Hydra. Copyright © 2007 John Wiley & Sons, Ltd.
MSK regulate TCR‐induced CREB phosphorylation but not immediate early gene transcription
Authors: Kaiser Madlen , Wiggin Giselle R. , Lightfoot Kurt , Arthur J. Simon C. , Macdonald Andrew 
Published: August 2007

AbstractStimulation of the T cell receptor activates the ERK1/2 and p38 mitogen‐activated protein kinase (MAPK) cascades. We demonstrate that TCR stimulation also activates the mitogen‐ and stress‐activated kinases (MSK) downstream of ERK1/2 and p38 in both a T cell line and primary peripheral T cells. MSK1/2‐knockout mice were found to have normal numbers of T cells in the thymus, and development of these cells appeared unaffected. Using naive T cells and T lymphoblasts from MSK1/2‐knockout mice, it was found that MSK was the kinase responsible for phosphorylation of the transcription factor CREB in response to TCR stimulation. Phosphorylation of CREB by MSK has been linked to the transcription of nur77, nor1 and c‐fos downstream of MAPK signalling in various cell types. In T cells, the TCR‐dependent transcription of these genes was found to require a MAPK‐dependent but MSK‐independent signalling pathway. Nevertheless, the number of T cells present in the spleens of MSK1/2‐knockout mice and the IL‐2‐induced proliferation of these cells was reduced compared to wild‐type mice. This correlated to a reduction in the TCR‐induced up‐regulation of the IL‐2 receptor CD25 and a requirement for MSK in IL‐2‐induced CREB phosphorylation.
Simultaneous Determination of Ranitidine and Metronidazole at Glassy Carbon Electrode Modified with Single Wall Carbon Nanotubes
Authors: Salimi Abdollah , Izadi Mohadeseh , Hallaj Rahman , Rashidi Manochehr 
Published: August 2007

AbstractSingle‐walled carbon nanotubes(SWCNTs) were dispersed into DMSO, and a SWCNTs‐film coated glassy carbon electrode was achieved via evaporating the solvent. The results indicated that CNT modified glassy carbon electrode exhibited efficiently electrocatalytic reduction for ranitidine and metronidazole with relatively high sensitivity, stability and life time. Under conditions of cyclic voltammetry, the potential for reduction of selected analytes is lowered by approximately 150 mV and current is enhanced significantly (7 times) in comparison to the bare glassy carbon electrode. The electrocatalytic behavior is further exploited as a sensitive detection scheme for these analytes determinations by hydrodynamic amperometry. Under optimized condition in amperometric method the concentration calibration range, detection limit and sensitivity were about, 0.1–200 μM, detection limit (S/N=3) 6.3×10−8 mol L−1 and sensitivity 40 nA/μM for metronidazole and 0.3–270 μM 7.73×10−8 mol L−1 and 25 nA/μM for ranitidine. In addition, the ability of the modified electrode for simultaneous determination of ranitidine and metronidazole was evaluated. The proposed method was successfully applied to ranitidine and metronidazole determination in tablets. The analytical performance of this sensor has been evaluated for detection of these analytes in serum as a real sample.
Computational and rapid expected annual loss estimation methodologies for structures
Authors: Solberg Kevin M. , Dhakal Rajesh P. , Mander John B. , Bradley Brendon A. 
Published: August 2007

AbstractExpected annual loss (EAL), which can be expressed in dollars, is an effective way of communicating the seismic vulnerability of constructed facilities to owners and insurers. A simplified method for estimating EAL without conducting time‐consuming non‐linear dynamic analyses is presented. Relationships between intensity measures and engineering demand parameters resulting from a pushover analysis and a modified capacity‐spectrum method are combined with epistemic and aleatory uncertainties to arrive at a probabilistic demand model. Damage measures are established to determine thresholds for damage states from which loss ratios can be defined. Financial implications due to damage can then be quantified in the form of EAL by integrating total losses for all likely earthquake scenarios. This rapid loss estimation method is verified through the computationally intensive incremental dynamic analysis, with the results processed using a distribution‐free methodology. To illustrate the application of the proposed method, the seismic vulnerability of two highway bridge piers is compared; one bridge is traditionally designed for ductility while the other is based on an emerging damage avoidance design (DAD) philosophy. The DAD pier is found to have a clear advantage over the conventional pier; the EAL of the DAD pier is less than 20% of its ductile counterpart. This is shown to be primarily due to its inherent damage‐free behaviour for small to medium earthquake intensities, whose contribution to EAL is significantly more than that of very rare events. Copyright © 2007 John Wiley & Sons, Ltd.
Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients
Authors: Nattermann Jacob , Vogel Martin , Berg Thomas , Danta Mark , Axel Baumgarten , Mayr Christoph , Bruno Raffaele , Tural Christina , Klausen Gerd , Clotet Bonaventura , Lutz Thomas , Grünhage Frank , Rausch Michael , Nischalke Hans Dieter , Schewe Knud , Bienek Bernhard , Haerter Georg , Sauerbruch Tilman , Rockstroh Juergen K. , Spengler Ulrich 
Published: August 2007

Abstract

Hepatitis C virus (HCV)/human immunodeficirency virus (HIV) coinfection poses a difficult therapeutic problem. Response to HCV-specific therapy is variable but might be influenced by host genetic factors, including polymorphisms of cytokine genes. Here, we studied whether interleukin-6 (IL-6) C174G gene polymorphism affects the response to antiviral treatment in HCV-infected HIV-positive subjects. We determined IL-6 genotypes in HIV-positive patients with acute (n = 52) and chronic (n = 60) hepatitis C treated with pegylated interferon-α. Two hundred ten HCV monoinfected, 197 HIV monoinfected, and 100 healthy individuals were studied as controls. Patients were classified into high and low producers according to IL-6 genotypes. Rates of sustained virological responses (SVRs) were compared between the IL-6 genotypes. Signal transducer and activator of transcription three phosphorylation was analyzed by Western blot in HCV core-transfected human hepatoma cell line (HUH7) cells. Distribution of IL-6 genotypes did not differ significantly between the study groups. SVR was achieved in 63% of HIV/HCV coinfected patients. Carriers of the IL-6 high producer (HP) genotype had significantly higher SVR rates than patients with an IL-6 low producer genotype (70.1% versus 52%;

P

< 0.002). This effect was seen in both HIV-positive patients with acute (74% versus 33%;

P

< 0.05) and chronic (66% versus 33%;

P

< 0.05) hepatitis C. Multivariate analysis confirmed IL-6 HP carriage as an independent positive predictor for SVR (Odd′s ratio 6.1;

P

= 0.004). This effect corresponds to the

in vitro

observation that in HCV core-transfected HUH7 cells, IL-6 overcomes the HCV core-mediated inhibition of STAT3 activation.

Conclusion:

Response rates to HCV-specific treatment are higher in HCV/HIV-positive patients carrying the IL-6 HP genotype, which might be because of IL-6 mediated STAT3 activation. (HEPATOLOGY 2007.)
Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease
Authors: Montano-Loza Aldo J. , Carpenter Herschel A. , Czaja Albert J. 
Published: August 2007

Abstract

Autoimmune hepatitis may fail to respond to corticosteroid therapy, but the frequency and bases for this outcome are uncertain. We aimed to determine the frequency and nature of treatment failure in patients with type 1 autoimmune hepatitis, define features associated with its occurrence, and assess if the model for end-stage liver disease can predict this outcome. Patients failing conventional corticosteroid regimens were compared to patients who responded to similar regimens. Fourteen of 214 patients (7%) failed corticosteroid treatment. Patients who failed therapy were younger (33 ± 3 years versus 48 ± 1 years,

P

= 0.0008), had higher serum levels of bilirubin at accession (4.1 ± 0.9 mg/dL versus 2.3 ± 0.2 mg/dL,

P

= 0.02), presented acutely more frequently (43% versus 14%,

P

= 0.01), and had a higher frequency of HLA (human leukocyte antigen) DRB1*03 (93% versus 53%,

P

= 0.004) than did patients who achieved remission. An alternative disease (fatty liver disease) emerged in only 1 patient who failed therapy (7%). Scores determined by the model of end-stage liver disease at presentation of patients who failed treatment were higher than those of who achieved remission (16 ± 1 versus 10 ± 0.3 points,

P

< 0.0001), and score greater than 12 points had greater sensitivity (97%) and specificity (68%) for treatment failure than did HLA DRB1*03 or other features.

Conclusion:

Onset at an early age, acute presentation, hyperbilirubinemia, and presence of HLA DRB1*03 characterize patients who fail corticosteroid treatment. The model for end-stage liver disease may be a useful instrument for identifying patients prone to this outcome. (HEPATOLOGY 2007.)
Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin
Authors: Schaefer Martin , Hinzpeter Axel , Mohmand Ariane , Janssen Gesa , Pich Maurice , Schwaiger Markus , Sarkar Rahul , Friebe Astrid , Heinz Andreas , Kluschke Michael , Ziemer Marlene , Gutsche Juri , Weich Viola , Halangk Juliane , Berg Thomas 
Published: August 2007

Abstract

We investigated and compared the results of treating the chronic hepatitis C (HCV) infection of different groups of psychiatric-risk patients and controls with pegylated interferon alpha (pegIFN-α) plus ribavirin. Seventy patients were prospectively screened for psychiatric disorders. Seventeen patients without psychiatric diseases or drug addiction (controls), 22 patients with psychiatric disorders, 18 patients who had received methadone substitution treatment and 13 patients who were former drug users were treated with pegIFN-α plus ribavirin. Sustained virological response (SVR), adherence, and psychiatric side effects (using the Montgomery-Asberg Depression Rating Scale and the Brief Psychiatric Rating Scale) in the groups were compared. An SVR was found in 58.6% of all patients: 58.8% of the controls, 50% of psychiatric patients, 72.2% of methadone patients, and 53.8% of former drug users. Methadone-substituted patients and former drug users had significantly higher dropout rates. Scores for neither depressive nor psychotic symptoms differed significantly between groups during treatment. However, the controls had lower pretreatment scores, followed by a significant higher increase to maximum scores. A stepwise logistic regression model showed that only genotype, not group (control, psychiatric, methadone, or former drug abuse), type of psychiatric diagnosis (affective disorder, personality disorder, or schizophrenic disorder), depression scores before and during treatment, change in depression score, antidepressive treatment, sex, or liver enzymes before treatment, was associated with SVR.

Conclusion:

In an interdisciplinary treatment setting psychiatric diseases and/or drug addiction did not negatively influence psychiatric tolerability of and antiviral response rate to HCV treatment with pegIFN-α and ribavirin. (HEPATOLOGY 2007.)